The QualityStocks Daily Wednesday, May 29th, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (ELTK) +326.83%

PoliticsAndMyPortfolio (TURA) +109.15%

SmallCapRelations (RNWR) +92.31%

The QualityStocks Daily Stock List

Fortem Resources, Inc. (FTMR)

Stock Target Advisor, StockScores, Stock Alert, Marketbeat, OTC Markets, Teletrader, Private Capital Newswire, Infront Analytics, Real Investment Advice, Market Screener, Stockwatch, MarketWatch, InvestorsHub, and Stockhouse reported previously on Fortem Resources, Inc. (FTMR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Fortem Resources, Inc. is an oil and gas corporation that holds properties in Alberta and Utah. It engages in the exploration, development and production of crude oil and natural gas in the Western Canadian Sedimentary Basin and Utah in the United States. Fortem Resources has its Calgary, Alberta operations office and its North Orem, Utah operations office.

A diversified natural resource enterprise, the Company is seeking North American and global expansion via an acquisition strategy. Fortem seeks out, evaluates and acquires working interests (WIs) in oil and gas and other resource projects in North America and worldwide. Its strategy remains centered on developing quality energy projects with lower risk profiles and identified upside potential.

The Company holds five wholly-owned subsidiaries named Rolling Rock Resources, Black Dragon Energy, Colony Energy, Big Lake Energy and City of Gold. Withstanding City of Gold, the remaining four companies hold greater than 350,000 acres of prolific oil and gas fields, with proven reserves, production and future development for 2019.

Fortem Resources has come across a rare global gold mining asset in Myanmar, South Asia. With 465 square kilometers of mining area, City of Gold has the potential of unlocking one of the largest gold mines in the world. Fortem has appointed a highly qualified team with more than three decades in the minerals industry.

Fortem Resources is concentrating on optimizing its present assets to enhance Company value. It continues to increase its asset base on acquisitions, farm-ins, joint ventures (JVs) and land sale purchases. It is targeting high WI opportunities with year-round access, strong growth, and economic potential in proven oil and gas areas throughout the world. Moreover, it is searching for regions with low geological risk and the potential for high netback revenues.

Last week, Fortem Resources announced that it is in the process of starting field operations via its wholly-owned subsidiary Colony Energy, LLC at its Godin Property in north central Alberta. Colony has the rights to an undivided 100 percent WI in a total of 80 contiguous sections (51,200 acres) in addition to its 20 contiguous sections (12,800 acres) of heavy oil leases in north central Alberta. Colony Energy has prepared tenders. It is seeking bids from different service companies to put its first well on its Godin property in production.

Fortem Resources, Inc. (FTMR), closed Wednesday's trading session at $1.70, even for the day, on 1,878 volume with 6 trades. The average volume for the last 3 months is 10,225 and the stock's 52-week low/high is $1.34/$3.95.

chart

Sanara MedTech, Inc. (WNDMD)

Stock Target Advisor, Stock News Feed, Zacks, Penny Stock Hub, Interactive Brokers, Trading View, OTC Markets, Market Screener, Real Investment Advice, Investors Hangout, Stockhouse, and InvestorsHub reported earlier on Sanara MedTech, Inc. (WNDMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Sanara MedTech, Inc. is a provider of surgical and chronic wound care products. These products are dedicated to improving patient outcomes. The Company’s emphasis is on improving patient outcomes with evidenced-based healing solutions. Sanara MedTech previously went by the name WNDM Medical, Inc. The Company is headquartered in Fort Worth, Texas.

Sanara MedTech develops, markets and distributes biotechnology products to physicians, hospitals, clinics and all post-acute care settings. The Company sells and distributes CellerateRX® Surgical Activated Collagen® Adjuvant and HemaQuell® Resorbable Bone Hemostat. Its main products sell in the North American advanced wound care and surgical tissue repair markets.

Sanara MedTech’s approach to product development combines science and technology with the aim of creating unique, safe and cost-effective products for the ever-changing surgery landscape. The Company’s products are valid in the majority of surgical specialties.

Sanara’s CellerateRX® Surgical is changing collagen’s role in the operating room across specialties where comorbidities and postoperative incisional healing risks are a concern. CellerateRX provides collagen’s benefits to the incision. It is 1/100th the average size of intact native collagen molecules. It helps seal and protect wounds from further physical and bacterial injury.

HemaQuell® is a patented resorbable bone hemostat. It is a new type of resorbable, water-soluble bone hemostat that controls bleeding with an innovative and user-friendly application tube. HemaQuell Hemostat provides hemostasis and is resorbed in 2-7 days to allow normal bone fusion and healing.

This month, Sanara MedTech announced that the Board of Directors elected Mr. Ronald T. Nixon as Executive Chairman of the Board. Moreover, the Company introduced three new Food and Drug Administration (FDA) cleared products at the Symposium on Advanced Wound Care (SAWC) Conference in San Antonio, Texas from May 8-10, 2019.

Sanara MedTech is concentrating on developing and commercializing products for six areas of wound and skin care. These include debridement, biofilm management, hydrolyzed collagen, placental biologics, adjunct products for Negative Pressure Wound Therapy, and oxygen delivery systems for the wound bed. Further to new product introductions, the Company continues to center on the expansion of its distribution channel for the CellerateRX® surgical product line.

Sanara MedTech, Inc. (WNDMD), closed Wednesday's trading session at $4.00, up 2.56%, on 220 volume with 4 trades. The average volume for the last 3 months is 1,077 and the stock's 52-week low/high is $2.00/$10.00.

chart

Ionix Technology, Inc. (IINX)

Marketbeat, StockScores, Street Insider, Market Screener, Financial Content, Market Exclusive, Wallmine, YCharts, Stockhouse, PR Newswire, and Simply Wall St reported previously on Ionix Technology, Inc. (IINX), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Ionix Technology, Inc. is a business aggregator in photoelectric display and smart energy fields. It has four operating subsidiaries. The Company was previously known as Cambridge Projects, Inc. It changed its name to Ionix Technology, Inc. in February of 2016. Ionix Technology is a subsidiary of Shining Glory Investments Limited. Established in 2011, Ionix has its head office in Reno, Nevada.

The Company’s four operating subsidiaries include Changchun Fangguan Photoelectric Display Technology Co., Ltd. This subsidiary specializes in developing, designing, producing, and selling TN and STN LCD, STN, CSTN, and TFT LCD modules, and other related products.

Its Shenzhen Baileqi Electronic Technology Co., Ltd. subsidiary specializes in LCD slicing, filling, researching and designing, manufacturing and selling of LCD Modules (LCM) and PCBs. The Lisite Science Technology (Shenzhen) Co., Ltd. subsidiary engages in the production of intelligent electronic devices. The Dalian Shizhe New Energy Technology Co., Ltd. subsidiary engages in photovoltaic power generation, electric vehicles and charging piles with corresponding operation and maintenance and three dimensional parking.

Earlier this month, Ionix Technology announced its financial results for the three months ended March 31, 2019. Total revenues grew by 146 percent from the three months ended March 31, 2018 to the three months ended March 31, 2019. Gross Profit Margin was 22 percent during the three months ended March 31, 2019 versus 11 percent for the three months ended March 31, 2018.

Mr. Yubao Liu, Chief Executive Officer of Ionix Technology, said, "We are taking a persistent approach to build our business and continue to make investments in the fields of photoelectric display and smart energy. By integrating such operations we will gain competitive advantage and economic scale. The recent plan to accelerate investment in the OLED flexible screen market is a good example. We expect these efforts bring long-term growth for our shareholders."

Ionix has embarked on the layout of industrialization and marketization of front end materials and back end modules of liquid crystal displays and applications of flexible folding display technology through taking Changchun Fangguan and Shenzhen Baileqi as production bases, to capture the market share of OLED high technology.

Ionix Technology is scheduled to present at the 9th Annual LD Micro Invitational Conference, June 4-5, 2019, at the Luxe Sunset Hotel – Bel Air, California. Ionix will be presenting at 11:20 AM PT on June 5, 2019. The presentation will provide an overview of its business model, financial highlights, as well as growth strategy. Company management will also conduct 1-on-1 meetings at the conference.

Ionix Technology, Inc. (IINX), closed Wednesday's trading session at $1.80, up 0.56%, on 500 volume with 4 trades. The average volume for the last 3 months is 2,308 and the stock's 52-week low/high is $1.019/$2.75.

chart

BioCardia, Inc. (BCDA)

StockTwits, Zacks, Insider Tracking, Street Insider, Stockopedia, Marketbeat, Capital Cube, Wallet Investor, AI Stock Finder, Dividend Investor, Barchart, and Stockhouse reported previously on BioCardia, Inc. (BCDA), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BioCardia, Inc. is a leader in the development of comprehensive solutions for cardiovascular regenerative therapies. The Company’s biotherapeutic product candidates in clinical development are CardiAMP and CardiALLO cell therapies. A clinical-stage regenerative medicine company, BioCardia has its corporate headquarters in San Carlos, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

BioCardia also offers the Helix biotherapeutic delivery system; and the Morph vascular access product line, which provides catheter products. The Company’s lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System. It provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications. These are heart failure that develops after a heart attack and chronic myocardial ischemia.

BioCardia’s second therapeutic candidate is the investigational CardiALLO™ Cell Therapy System. This is an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells, which have been identified to meet specified criteria. The therapy has the potential to be advanced for numerous clinical indications. This includes heart failure.

Earlier in May, BioCardia announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AVANCE™ steerable introducer product family, designed for introducing different cardiovascular catheters into the heart. This includes through the left side of the heart via the interatrial septum.

The AVANCE steerable introducer family takes advantage of Morph “DNA” technology. This is an enhancement of BioCardia’s FDA-cleared Morph steerable introducer that adds a number of features that make the devices ideal for use in transseptal procedures and are designed to improve upon commercially-available offerings.

BioCardia also partners with other biotherapeutic companies. This is to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, as well as acute myocardial infarction.

Last week, BioCardia announced positive results from a study of its Helix™ Biotherapeutic Delivery System for cell therapy used to treat patients early following acute myocardial infarction (AMI) to prevent long term heart failure. The results were presented on May 23, 2019 at EuroPCR by Christina Paitazoglou, MD, with the Cardiologicum Hamburg, Germany during a Hot Line/Late Breaking Trials session of inventive first-in-man trials and early phase studies entitled “Early transendocardial injection of autologous bone marrow-derived mononuclear cells following ischaemic myocardial events: the Alster-Helix registry.”

Dr. Paitazoglou in her presentation said, “Results suggest that intramyocardial cell therapy possibly improves left ventricular function and symptoms by attenuating myocardial remodeling on top of successful PCI and optimal standard care after AMI. Results (for the Helix™ system) are similar to the NOGA-treated patients, as previously observed in the ALSTER stem cell trial.”

BioCardia, Inc. (BCDA), closed Wednesday's trading session at $1.09, down 14.84%, on 1,825 volume with 5 trades. The average volume for the last 3 months is 4,163 and the stock's 52-week low/high is $0.89/$3.579.

chart

Drone Aviation Holding Corp. (DRNE)

The Hot Penny Stocks, Street Insider, Otc.Watch, Biz Journals, Zacks, 4-Traders, Wallet Investor, Stockhouse, Equity Clock, InvestorsHub, The Street, and Market Screener reported earlier on Drone Aviation Holding Corp. (DRNE), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Drone Aviation Holding Corp. is a developer of specialized, tethered aerial monitoring and communications platforms serving national defense and homeland security customers. The Company develops and manufactures cost-effective, compact and rapidly deployable aerial platforms. These include lighter-than-air aerostats and drones designed to provide government and commercial customers with enhanced surveillance and communication capabilities. Incorporated in 2014 and OTCQB-listed, Drone Aviation is based in Jacksonville, Florida.

The Company’s specialized tethered aerial monitoring and communications platforms are for use in applications including intelligence, surveillance and reconnaissance (ISR) and communications. The design of its products are for military and security applications where they can provide secure and reliable aerial monitoring for extended durations. This is while being tethered to the ground by way of a high strength armored tether.

Drone Aviation concentrates mainly on the development of a tethered aerostat known as the Winch Aerostat Small Platform (WASP). It has been purchased by tier-one customers. These include the U.S. Department of Defense and the Department of Homeland Security. Common applications of WASP include extending network communications and intelligence, surveillance and reconnaissance.

The Company’s WASP Lite uses the proven fieldability of Drone Aviation’s larger WASP Aerostat System. It offers a smaller footprint for expeditionary missions. WASP Lite can fit in the back of a pickup truck, or on a boat or UTV. Moreover, the Company’s FUSE Tether System is a tether kit for unlimited flight time. It maximizes a customer’s drone investment through attaining safe and reliable operation via ground power.

Regarding Drones, the Company has its WATT 200. The design of it is for ease of use, making it ideal for commercial operators. It also has its WATT 300. The design of it is as a heaver-lift tethered drone created for multi-mission requirements.

This month, Drone Aviation Holding announced that it received its first contract award for its newly designed aerostat product, the WASP Lite, from a U.S. Army customer. WASP Lite is the culmination of considerable product development and testing, which successfully completed training and operational evaluations conducted at numerous U.S. Army bases.

Under the terms of the award, valued at greater than $1.1 million, Drone Aviation will supply multiple WASP Lite aerostat systems capable of enhancing and extending the modern networked battlefield supporting specialized waveform communications equipment and day/night ISR (Intelligence, Surveillance and Reconnaissance) payloads.

Drone Aviation Holding Corp. (DRNE), closed Wednesday's trading session at $1.00, up 9.87%, on 2,501 volume with 6 trades. The average volume for the last 3 months is 8,103 and the stock's 52-week low/high is $0.36/$2.00.

chart

International Land Alliance, Inc. (ILAL)

OTC Markets, StockNews, Stockwatch, GlobeNewswire, Interactive Brokers, Simply Wall St, and Investors Hangout reported earlier on International Land Alliance, Inc. (ILAL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

International Land Alliance, Inc. is a global land investment and development organization listed on the OTC Markets’ OTCQB. Its emphasis is on acquiring attractive raw land chiefly in Northern Baja California, often within driving distance from Southern California. The Company’s main objective is to sell desirable properties, at competitive prices, with favorable financing options for individual purchases and/or bulk purchases suitable for all kinds of investors and buyers. International Land Alliance has its corporate headquarters in San Diego, California.

The Company’s inventory includes properties that are residential, commercial, recreational, waterfront, ranch, hotel, and marina. International Land Alliance, by way of its wholly-owned subsidiary, International Land Alliance, S.A. de C.V, a Mexican corporation, is the owner of 123 residential lots and commercial lots consisting of a total of 20-acres, known as Valle Divino, located in Ensenada, Baja California. It is also the owner of 1,344 residential lots and commercial lots consisting of 497-acres, known as Oasis Park Resort, located in San Felipe, Baja California.

The Oasis Park Resort and Valle Divino Resort projects will undergo development as a second home resort or retirement destination in a planned community setting. The Company’s Villas Del Enologo at Rancho Tecate is a 2.6 Acre Parcel within the prestigious Rancho Tecate. It is a planned 24 -2B/2B Vineyard Villas with private wine cellar.

On March 18, 2019, International Land Alliance closed on the purchase of 80 acres, the Emerald Grove Estates, and an 8,000 square foot event facility, the Chateau at Emerald Grove, in the wine country in Southern California for $1.1 million. The Company entered into a 3-year lease with future plans of development.

International Land Alliance offers the option of financing with a guaranteed acceptance on any purchase for every customer. Through removing the middleman, loans are approved directly by the Company. This provides easy and affordable financing terms. Moreover, there are no prepayment penalties, credit or background checks, and very competitively low interest rates.

Overall, International Land Alliance owns a total of four different real estate development properties comprising almost 600 acres of land. These properties are all in southern California or Northern Baja California, Mexico. The Company states that upon full development, the properties could potentially yield 1,510+ residential lots and 11 commercial lots, all of which it intends to sell.

To date (as of April 30, 2019), the Company spent roughly $5.4 million buying land and developing land that it has purchased. Those same assets have recently been appraised at $16.4 million. This represents an increase of more than 300 percent in value.

Last week, International Land Alliance announced it started final site preparation on its Valle Divino development. Valle Divino is part of a 1,250-acre master planned residential community overlooking the internationally-renowned Bajamar Ocean Front Hotel and Golf Course and the Pacific Ocean.

                   

International Land Alliance, Inc. (ILAL), closed Wednesday's trading session at $1.16, down 8.48%, on 700 volume with 3 trades. The average volume for the last 3 months is 887 and the stock's 52-week low/high is $0.50/$5.00.

chart

Item 9 Labs Corp. (INLB)

Invest Tribune, Financial Buzz, Investors Hangout, Trading View, Stockwatch, Dividend Investor, GuruFocus, Equity Clock, CannabisMarketCap, Pot Stock News, Tip Ranks, Market Screener, Financial Content, Stockhouse, Wallet Investor, GlobeNewswire, Business Insider, InvestorsHub, and OTC Markets reported beforehand on Item 9 Labs Corp. (INLB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Item 9 Labs Corp. is a leader in comfortable cannabis health solutions for the modern consumer. The Company is bringing best of industry practices to markets throughout the nation by way of cultivation and production, distinct retail environments, licensing services, and diverse product groups. It caters to different medical cannabis demographics. Item 9 Labs has its head office in Phoenix, Arizona. In addition, it has medical cannabis operations in manifold U.S. markets. The Company lists on the OTC Markets.

Item 9 Labs’ asset portfolio includes Dispensary Permits, Dispensary Templates, and Strive Life. Dispensary Permits is its consulting firm. It specializes in strategic license application and compliance. Dispensary Templates, a subdivision of the company, is a technology platform with an extensive digital library of licensing and business planning resources.

Strive Life is a turnkey dispensary model for the retail sector. It improves the patient experience with consistent and premier service, high-end design, and precision-tested products. It is currently undergoing implementation in the States of Arizona and North Dakota.

Item 9 Labs has also created complementary brands - Item 9 Labs and Strive Wellness - to channel consumer diversity. Propriety delivery platforms include the Apollo Vape and Pod system, as well as a pioneering intra-nasal device. Item 9 Labs has received numerous accolades for its medical-grade flower and concentrates.

The Company will be managing cultivation, processing, distribution, and dispensary operations in up to ten U.S. markets by the end of 2019. Current facilities include distribution and processing operations - Strive Wellness of Ohio and Strive Wellness of Nevada, and a dispensary - Strive Life North Dakota.

Item 9 Labs’ corporate plan includes completing the 20,000 square-foot construction of the Strive Wellness of Nevada processing facility in Q4 2019. It also plans on continuing expansion of its distribution and sales network.

Last week, Item 9 Labs announced that medical marijuana dispensary Strive Life Grand Forks, a partner following the Company’s Strive Life business model and brand, would officially open on Wednesday, May 22nd, at 1809 13th Avenue North, in Grand Forks, North Dakota. This operation will offer a varied inventory of patient-focused products. Strive Life Grand Forks implements medical marijuana dispensary best practices from across the U.S. and worldwide.

Sara Gullickson, Chief Executive Officer of Item 9 Labs, said, “Strive Life will offer a diverse inventory of quality products and quality medical cannabis solutions. We received a warm welcome from the Grand Forks community at our soft opening and now we are ready to serve North Dakota patients.”

Item 9 Labs Corp. (INLB), closed Wednesday's trading session at $5.30, even for the day, on 113 volume with 3 trades. The average volume for the last 3 months is 4,450 and the stock's 52-week low/high is $1.50/$8.39.

chart

Integrity Applications, Inc. (IGAP)

Stockflare, Wallet Investor, MarketWatch, Simply Wall St, Stockopedia, PR Newswire, SmallCapVoice, Morningstar, Market Exclusive, Wallmine, Market Screener, OTC Markets Group, GuruFocus, Capital Cube, and YCharts reported previously on Integrity Applications, Inc. (IGAP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Integrity Applications, Inc. is the maker of GlucoTrack® - a non-invasive device for measuring glucose levels in people with type 2 diabetes and pre-diabetes. GlucoTrack® is a monitoring device that quickly measures and displays an individual's glucose level in about a minute without finger pricking or any pain. OTCQB-listed, Integrity Applications is headquartered in Wilmington, Delaware. The Company has a research and development (R&D) site in Ashdod, Israel.

Integrity Applications is focusing on three important initiatives - GlucoTrack Commercialization in Europe; GlucoTrack U.S. FDA (Food and Drug Administration) Approval; and a Product Roadmap. The Company’s initial principal emphasis is on the commercialization of GlucoTrack in Europe. GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and pre-diabetes. It is now in the early stages of commercialization in Europe, South Korea, as well as other geographies.

GlucoTrack® features a small sensor. This sensor clips to the earlobe and measures the user's glucose level using inventive and patented sensor technology. The measured signals undergo analysis using a proprietary algorithm and subsequently a calculated glucose level is displayed on a small handheld device the size of a small mobile phone.

The glucose results are stored in the device and used to project an estimated HbA1c level using a proprietary algorithm. The device can also display glucose values graphically. This allows the user to monitor glucose levels over time. GlucoTrack® is presently experimental in the United States. It is limited to investigational use only.

In December of 2018, Integrity Applications announced that it launched a Customer Experience Program in the Netherlands with its exclusive distributor MediReva and renowned clinical thought leaders in the field of diabetes care. The chief purpose of this program is to demonstrate real-world patient and health care professional experience with GlucoTrack® as a solution for daily glucose monitoring, and to further hasten commercialization and the reimbursement process in the Netherlands.

Integrity Applications, Inc. (IGAP), closed Wednesday's trading session at $0.25, up 47.06%, on 5,300 volume with 5 trades. The average volume for the last 3 months is 798 and the stock's 52-week low/high is $0.10/$2.00.

chart

Right On Brands, Inc. (RTON)

Penny Stock Hub, 4-Traders, InvestorsHub, Morningstar, Investors Hangout, SmallCapVoice, last10k, Interactive Brokers, MarketWatch, OTC Markets, Wallet Investor, YCharts, Simply Wall St, Barchart, Stockhouse, Capital Cube, Penny Stock Vault, Stockwatch, Stockopedia, and Investors News Magazine reported earlier on Right On Brands, Inc. (RTON), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Right On Brands, Inc. is a consumer goods company based in Santa Monica, California. It specializes in the brand development of health conscious, hemp-infused food and beverage products. Right On Brands consists of three subsidiaries. These are Endo Brands, Humble Water Company, and Humbly Hemp. Right On Brands’ shares trade on the OTC Markets.  

The Company is developing, marketing, and investing in industrial hemp, cannabis, adaptogenic superfoods and natural water for a new generation of health-conscious consumers. Endo Water is pH balanced and micro-clustered for antioxidant protection. Additionally, Endo Water is oxygenated for improved performance and energy.

Endo Water is infused with a 99.5 percent pure CBD oil, processed using Nano Technology. This makes the particles one-millionth of its normal size. The process permits the Nano-Sized CBD's to immediately penetrate one’s cells versus the lengthy process of being absorbed by the body's digestive system.

Right On Brands created a joint venture (JV) with Centre Manufacturing, LLC to create ENDO Labs. ENDO Labs was established to fill the void in the hemp derived CBD market for the creation and manufacturing of quality formulated CBD products. ENDO labs can formulate food, beverage, skin-care/topical, supplements, and pet. It can also take on advanced formulations and products to any customers’ preference. ENDO Labs will also have the function of brokering CBD oil for its customers and clients. Right On Brands has 51 percent ownership of the JV with Medical Biochemist Dr.  Ashok Patel's Centre Manufacturing.

Humbly Hemp is a product line of hemp-based products. Each Humbly Hemp bar is kosher, vegan, soy free, dairy free, and gluten-free. Furthermore, they are free of all top 11 allergens. The foundation of Right On Brands’ protein bars is with gluten free rolled oats, hemp seeds, and plant protein.

The Humble Water Company product is a natural spring water sourced from an ancient ice age aquifer at the foothills of the Rocky Mountains located at the only triple watershed in North America. Humble Water is pure and high in natural alkalinity.

Recently, Right on Brands announced it will be entering the lucrative health and wellness business with one of the Southwest's first full-service CBD based wellness centers. The corporate showcase ENDO Wellness Center is scheduled to open summer 2019 in Dallas, Texas. Right on Brands/Endo Brands, Inc, the maker of Endo Water will also be opening a regional distribution warehouse in Addison Texas on Midway Lane later this month.

Right On Brands, Inc. (RTON), closed Wednesday's trading session at $0.0215, up 2.93%, on 201,950 volume with 14 trades. The average volume for the last 3 months is 192,801 and the stock's 52-week low/high is $0.0188/$0.231.

chart

Northwest Biotherapeutics, Inc. (NWBO)

RedChip,  Promotion Stock Secrets, OTC Picks, Wall Street Corner, BUYINS.NET, StockPicksNYC,  INO.com Market Report, Wealth Makers, SmallCapVoice, Wealthpire, Cool Penny Stocks, Street Insider, Pure Action Stocks, Pennybuster, The Street, FeedBlitz, All Penny Stocks,  Bull Rally, Marketbeat, Investor Place, and Streetwise Reports reported earlier on Northwest Biotherapeutics, Inc. (NWBO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northwest Biotherapeutics, Inc. is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. In the United States and Europe, the Company’s concentration is on developing personalized immunotherapy products, on a cost-effective basis, designed to treat cancers more effectively than contemporary treatments. This is without toxicities of the kind associated with chemotherapies. Northwest Biotherapeutics is based in Bethesda, Maryland and the Company lists on the OTCQB.

Northwest Biotherapeutics has a broad platform technology for DCVax dendritic cell-based vaccines. The Company is working to move ahead with numerous clinical programs, involving DCVax-L and DCVax-Direct. Northwest’s lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). This trial has completed its enrolment.

The Company is pursuing completion of the current Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer and pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs. This includes the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer that was previously announced.

Northwest’s product candidates also include DCVax-Prostate. The design of this product is specifically for late stage, hormone independent prostate cancer. The Company has developed a DCVax product line using a particular proprietary antigen — PSMA (Prostate Specific Membrane Antigen). The PSMA is produced via recombinant manufacturing methods. It is subsequently combined with the fresh, personalized dendritic cells to make DCVax-Prostate.

Northwest Biotherapeutics received clearance from the Food and Drug Administration (FDA) for a 612-patient Phase III trial in prostate cancer. It received approval in Germany of a five-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial. It is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It completed the 40-patient Phase I portion of the trial. Northwest is preparing for Phase II portions.

Recently, Northwest Biotherapeutics announced that it hired Mr. David Innes as Vice President, Investor Relations. Mr. Innes comes to the Company with more than 31 years of managing portfolios at major Wall Street firms, and a degree in biology.

Mr. Innes said, "After decades of focusing on small to mid-cap biotech and biomedical companies, I was attracted to NW Bio by what I believe is their broad potential, due to their approach to addressing the complexity of solid tumors which comprise most cancers. Their DCVax technology is precision-tailored to a patient's cancer, while also designed to mobilize a broad-spectrum attack on the cancer. As such, I believe NW Bio's DCVax technology has the potential to be a meaningful therapy for many types of solid tumor cancers."

Northwest Biotherapeutics, Inc. (NWBO), closed Wednesday's trading session at $0.32, up 0.31%, on 1,149,142 volume with 175 trades. The average volume for the last 3 months is 1,234,493 and the stock's 52-week low/high is $0.175/$0.349.

chart

Future Farm Technologies, Inc. (FFRMF)

Zacks, OTC Markets, Stockhouse, 4-Traders, InvestorsHub, MarketWatch, Insider Financial, Canadian Insider, GuruFocus, Technical420, Infront Analytics, Wallmine, PR Newswire, The Street, Morningstar, Barchart, Weed Newswire, Market News Updates, Trading View, Wallet Investor, and Market Screener reported earlier on Future Farm Technologies, Inc. (FFRMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Future Farm Technologies, Inc.’s business model includes developing and acquiring technologies, which will position it as a leader in the development of Controlled Environment Agriculture (CEA) for the worldwide production of varied kinds of plants, with an emphasis on cannabis. The Company has projects throughout North America. This includes California, Florida, and Maryland.

Future Farm Technologies has its Puerto Rico subsidiary, FFPR, LLC, that it owns jointly with TCG Investments, LLC, owner of the “Clínica Verde” brand. Future Farm Technologies’ Canadian subsidiary is CEPG Consulting and Design, Inc. of St. John’s, Newfoundland. Future Farm Technologies is headquartered in Vancouver, British Columbia.

The Company provides scalable, indoor CEA systems that use minimal land, water and energy regardless of climate, location or time of year. These systems are customized to grow an abundance of crops close to consumers. Additionally, Future Farm holds an exclusive global license to use a patented vertical farming technology that, when compared to traditional plant production methods, produces yields up to 10 times greater per square foot of land.

Future Farm also uses a leading cannabis oil extraction technology. This technology allows it to process 20lbs/hour of cannabis plant to yield roughly 908 grams/hour of oil. The Company also designs and distributes LED lighting solutions using the COB and MCOB technology.

Future Farm Technologies acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. It will work with its partner to merge AR and ad-tech with the cannabis industry via the CannaCube Live™ platform.

Recently, Future Farm Technologies announced that it entered into a new lease with Haymart, LLC to grow CBD-producing hemp on the same 100-acre parcel that it leased from Haymart for its inaugural 2018 season. This new lease covers the 2019 season. Moreover, it will cover the 2020 and 2021 seasons, unless either Future Farm or Haymart opt out. Under the terms of the lease, Haymart will also provide farming services to Future Farm Technologies.

Future Farm Technologies also recently announced that Mr. George Groccia, the Company’s Organizational and Operational Manager, and Mr. Zachary Lapan, General Manager for Future Farm Maine’s hemp production facilities, were selected to speak at the New England Cannabis Convention (NECANN) in Boston on Saturday, March 23, 2019. NECANN is the east coast’s largest cannabis industry event. It attracts the largest number of hemp and cannabis industry professionals in the Northeast.

Future Farm Technologies, Inc. (FFRMF), closed Wednesday's trading session at $0.091, down 0.55%, on 185,912 volume with 54 trades. The average volume for the last 3 months is 410,571 and the stock's 52-week low/high is $0.075/$0.46.

chart

EnviroLeach Technologies, Inc. (EVLLF)

Stock Market Revolution, Investopedia, Marketwired, Stockhouse, GuruFocus, 4-Traders, Dividend Investor, OTC Markets, Barchart, Streetwise Reports, MarketWatch, and Investors Hub reported previously on EnviroLeach Technologies, Inc. (EVLLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

EnviroLeach Technologies, Inc. is a technology business and near-term gold producer. It engages in the development and commercialization of environmentally-friendly formulas and technologies for the treatment of materials in the mining and E-Waste sectors. Its goal is to become a top gold producer through the “Urban-Mining” of end-of-life electronics and to be a significant player in the extraction of precious metals in the traditional mining space. EnviroLeach Technologies is headquartered in Burnaby, British Columbia.

The EnviroLeach reagent is well suited for the leaching of gold in an agitated or vat leach type process. This includes the treatment of whole ores, gravity concentrates, flotation concentrates, and also E-Waste. This segment of the market represents most of the global gold produced.

Using its proprietary non-cyanide, non-acid based process, EnviroLeach extracts precious and base metals from ores, concentrates, and E-Waste using only Food and Drug Administration (FDA) approved additives. EnviroLeach developed a unique, cost-effective and environmentally-friendly alternative to cyanide and strong-acid based processes now used for the extraction of precious metals from mineral ores, concentrates, and E-Waste.

The process is alike to the standard cyanide vat leaching circuits used today. However, it is much safer and simpler. The patent-pending EnviroLeach formula consists of combining five non-toxic, FDA approved dry ingredients with ambient temperature water. In 2017, EnviroLeach Technologies and Mineworx Technologies successfully advanced their proven chemical formulas and mechanical processes with a number of additional proprietary and patent-pending breakthroughs.

The new discoveries include major enhancements to the proven EnviroLeach E-Waste process regarding improved leach kinetics, improved recoveries, metal complex stability, element selectivity, metal precipitation and the reusability of the main solution. The two companies also completed the design, engineering and construction of the initial production scale, 10 tonne per day E-Waste processing plant that was installed on-schedule and on-budget at the Memphis, Tennessee facility.

Recently, EnviroLeach Technologies reported independent analytical results from SGS, a world leading inspection, verification, testing and certification company. The research work was commissioned by EnviroLeach Technologies as part of its enhanced third party, independent validation program.

The initial series of leach tests were conducted on high-grade samples. This includes gravity concentrate tails and flotation concentrates. Tests on oxidized material generated from autoclaving and roasting attained more than 94 percent within two hours. The results, using the EnviroLeach Technologies formulas, indicate that gold recoveries of greater than 85 percent were realized on the table tails within 24 hours and more than 90 percent recoveries from Flotation Concentrate within 24 hours.

Also recently, EnviroLeach Technologies announced that Company Management will present at the 31st Annual ROTH Conference on Monday, March 18, 2019, at 8:00AM Pacific Time at the Ritz Carlton Laguna Nigel in Dana Point, California.  Mr. Duane Nelson, Chief Executive Officer, will be participating on the panel of “Sustainability: How to Uncover Key Efforts & Initiatives which Drive Outperformance” on March 18 at 9:30-10:30AM. The EnviroLeach corporate presentation will be on Tuesday, March 19 at 2:30-3:00PM.

EnviroLeach Technologies, Inc. (EVLLF), closed Wednesday's trading session at $0.652, up 4.32%, on 40,720 volume with 27 trades. The average volume for the last 3 months is 65,319 and the stock's 52-week low/high is $0.449/$0.9996.

chart

ProMIS Neurosciences, Inc. (ARFXF)

Insider Financial, Uptick Newswire, Dividend Investor, Capital Cube, Penny Stock Hub, 4-Traders, Streetwise Reports, Stockhouse, TradingView, Investopedia, Wallmine, InvestorsHub, MarketWatch, and OTC Markets reported previously on ProMIS Neurosciences, Inc. (ARFXF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

ProMIS Neurosciences, Inc. focuses on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company’s lead product is PMN310 in Alzheimer’s disease. ProMIS Neurosciences has offices in Toronto, Ontario and Cambridge, Massachusetts. The Company lists on the OTC Markets Group’s OTCQB.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS™and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Utilizing this unique precision medicine approach, ProMIS is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.

The Company uses its proprietary technology platform to create highly selective antibodies. Its lead programs are following a “best in class” strategy targeting Amyloid beta in Alzheimer’s disease, with advantages over ”first in class” therapy from Biogen (aducanumab).

ProMIS’ PMN310 is on course to further confirm differentiation from likely “first in class” Biogen’s aducanumab. Furthermore, PMN310 is on course to start clinical trials in 2019 and potentially superior clinical data versus aducanumab in late 2021 soon after aducanumab expected approval.

For Alzheimer’s disease, ProMIS Neurosciences’ most advanced priority program, three validated product candidates have been designated. These are PMN310, PMN350, and PMN330. In January of 2018, ProMIS announced that its lead product candidate for Alzheimer's disease (AD), PMN310, showed absence of binding to amyloid beta (Aβ) plaque in and around blood vessels in AD brain samples in a preclinical study directly comparing PMN310 to other Aβ-directed antibodies.

ProMIS Neurosciences announced this past October the identification of novel targets on misfolded, pathological forms of tau. It said that the development of antibody therapeutics that selectively block these toxic forms of tau constitutes an exciting approach to treating Alzheimer's and other neurodegenerative diseases.

Last month, ProMIS Neurosciences announced the identification of a number of monoclonal antibody (mAb) drug candidates, which selectively target toxic forms of the protein alpha-synuclein, considered to be a root cause of Parkinson's disease (PD).

Dr. James Kupiec, the Company’s Chief Medical Officer, stated, "We used our proprietary discovery platform to generate several antibody drug candidates for Parkinson's disease that precisely target only the toxic forms of alpha-synuclein. Selectivity represents the essential feature of a successful antibody therapy, for it is critical that treatment not hinder normal forms of alpha-synuclein that play an important functional role in the brain.”

ProMIS Neurosciences, Inc. (ARFXF), closed Wednesday's trading session at $0.2089, up 4.50%, on 13,625 volume with 7 trades. The average volume for the last 3 months is 188,741 and the stock's 52-week low/high is $0.138/$0.3356.

chart

Fiore Gold Ltd. (FIOGF)

Investors Hangout, OTC Markets, MarketWatch, TradingView, Investorx, Stockhouse, Stockwatch, Wallet Investor, GuruFocus, Energy and Gold, Stock Orange, Barchart, Dividend Investor, The StreetWise Reports, Market Screener, WatchDog Stocks, Pinnacle Digest, The Street, and Morningstar reported previously on Fiore Gold Ltd. (FIOGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Fiore Gold Ltd. is a new America’s-focused gold producer and explorer listed on the OTC Markets Group’s OTCQB. The Company has the producing Pan Mine in Nevada. In addition, it has a group of exploration projects in Nevada, Washington and Chile. Fiore Gold has offices in Toronto, Ontario; Vancouver, British Columbia; and Englewood, Colorado.

Fiore Gold’s primary goal is to build a new mid-tier mining company in the world’s top mining jurisdictions. The Company’s initial aim is on becoming an 150,000-ounce/year gold producer. Pertaining to North American Projects, Fiore Gold’s assets include the producing Pan Mine near Eureka, Nevada. Assets also include the nearby Gold Rock exploration project. Furthermore, Fiore Gold controls the Golden Eagle advanced exploration project in Washington State.

The Pan Mine is a Carlin-style, sediment-hosted, gold-only deposit. Pan comprises three main zones of mineralization that has now been traced for greater than 6,000 feet along the north-south Branham Fault. The 2017 Pan Mine Feasibility Study (FS) defines Proven and Probable reserves of 318,000 gold ounces at an average grade of 0.51 g/t gold (0.015 oz/ton). The Company previously announced the start of exploration drilling at its Pan Mine, as part of a longer-term program intended to expand the resource and reserve base at Pan.

Concerning South American Properties, Fiore has its Pampas El Peñon properties; the Cerro Tostado project; and the Rio Loa property. The Pampas El Peñon property consists of 13 mining claims totaling 3,400 hectares. It is about 130 kilometers southeast of Antofagasta, Chile.

The Cerro Tostado (South America) project comprises five concessions totaling approximately1,500 ha located in Region II roughly 125 km southeast of Antofagasta. The Rio Loa property is in the northern part of the prolific Maricunga gold belt. The 1,000 Ha Rio Loa property is about 25 km south of Salares Norte.

This past December, Fiore Gold announced an updated resource estimate for its Pan open pit mine in White Pine County, Nevada following the completion of the 2018 resource expansion drilling program. The updated resource estimate includes Measured and Indicated (M+I) resources of 27.6 million tonnes grading 0.49 g/t containing 432,000 ounces of gold and Inferred Resources of 7.6 million tonnes grading 0.45 g/t containing 110,000 ounces of gold. The updated resource estimate has resulted in almost total replacement of roughly 19 months of mining depletion in the M+I category, and the addition (net of depletion) of roughly 38,000 gold ounces in the Inferred category.

Recently, Fiore Gold announced that its financial statements and management's discussion and analysis for the first fiscal quarter (Q1 2019) ended December 31, 2018, were filed with the securities regulatory authorities. For Q1 2019, the Company had Gold production of 9,765 ounces. This represents a 47 percent increase over Q1 2018. It had Gold sales of 9,744 ounces at an average realized price of $1,232 per ounce.

Fiore had Q1 2019 Pan Mine AISC (all-in sustaining costs) per ounce sold of $882 and cash costs per ounce sold of $812, versus Q1 2018 Pan Mine AISC per ounce sold of $1,704 and cash costs per ounce sold of $822. Q1 2019 Fiore consolidated AISC was $995 versus Q1 2018 Fiore consolidated AISC of $1,900.

Fiore Gold Ltd. (FIOGF), closed Wednesday's trading session at $0.23, up 5.54%, on 32,434 volume with 8 trades. The average volume for the last 3 months is 42,911 and the stock's 52-week low/high is $0.157/$0.469.

chart

The QualityStocks Company Corner

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, today announces it has selected the corporate communications expertise of NetworkNewsWire ("NNW").

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed the day's trading session at $0.0119, up 7.21%, on 2,597,708 volume with 73 trades. The average volume for the last 3 months is 2,559,759 and the stock's 52-week low/high is $0.0089/$0.0661.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings Inc. (CSE:TCAN) (XETR:TH8) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. To view the full publication, titled “Hunt for Perfect Acquisitions Reshapes Cannabis Industry,” please visit: http://cnw.fm/eLJi2.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $6.00, up 2.56%, on 85,465 volume with 113 trades. The average volume for the last 3 months is 161,491 and the stock's 52-week low/high is $0.769/$7.789.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is leveraging its patented technology platform to deliver powerful tumor-suppressing genes directly into cancer cells. Also today, NetworkNewsWire released a report on the company detailing how GNPX recently reported that it has retained the services of leading pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://nnw.fm/4arQW).

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.62, up 1.25%, on 17,570 volume with 45 trades. The average volume for the last 3 months is 36,740 and the stock's 52-week low/high is $0.95/$19.45.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Fueled by an explosion of CBD-infused edibles, billion-dollar projections for the CBD market may even be conservative. This seems possible when one considers the truly innovative work being done in the sector by the likes of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile), which has developed a patented delivery technology with disruptive potential, delivering 475% more CBD to the bloodstream after 15 minutes than conventional formulations.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.9799, up 0.56%, on 42,346 volume with 54 trades. The average volume for the last 3 months is 108,237 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech (OTCQB: ETST)is a Florida-based biotech company that offers the highest purity and quality full-spectrum, high-grade cannabinoids on the market. A recent article discussing the company reads, “ETST products are unique in that they offer one of the highest CBD profiles of any full-spectrum hemp oil on the market. To view the full article, visit: http://nnw.fm/T9YoR.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.48493, up 8.25%, on 45,863 volume with 27 trades. The average volume for the last 3 months is 35,380 and the stock's 52-week low/high is $0.375/$2.45.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions, Inc. (OTCMKTS: DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is excited to announce that it has signed a Letter of Intent (“LOI”) toward the establishment of a licensing agreement to acquire full and exclusive rights to market and distribute a two-time award-winning proprietary line of energy drinks under the DNA Energy Drink® brand designation. The Company intends to market both CBD-infused and non-CBD energy drinks.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset, WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed the day's trading session at $0.0175, up 1.45%, on 1,458,962 volume with 64 trades. The average volume for the last 3 months is 4,503,801 and the stock's 52-week low/high is $0.012/$0.14.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient’s innate immune system to fight disease. Drug candidates INKmune and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach to promote the body’s innate immune response to treat unsolved problems in medicine.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.48, off by 1.04%, on 5,746 volume with 48 trades. The average volume for the last 3 months is 17,959 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX VENTURE: OGI) (NASDAQ: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce it has recently shipped more than one hundred and thirty thousand units of pure cannabidiol (CBD) oil destined for markets across Canada.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., an original and leading Canadian licensed producer ("LP") of premium, quality cannabis and extract-based products. Founded in 2013 and headquartered in Moncton, New Brunswick, Canada, Organigram is focused on producing the highest-quality indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company's global footprint.?

Organigram delivers industry-leading yields and maximizes cannabis production at the lowest cultivation cost among other Canadian licensed producers. Organigram's high-tech facilities utilize an efficient, state-of-the-art mechanical room that includes both ethanol and CO2 extraction methods.

The company first began as a medical cannabis provider producing 5,000 kg/year (11,000 lbs) of 100 percent organic cannabis grown in pre-fabricated grow pods. Within two years, Organigram increased production to 36,000 kg/year (70,000 lbs) by utilizing an inventive, indoor 3-tier growing system. The company's pharmaceutical grade, state-of-the-art facility currently houses over 45,000 flowering plants growing at any one time.

Organigram's head office, production facility and research & development program are located on the company's 14-acre campus that houses several buildings and a 40-megawatt substation. Leading the way with a proprietary software system that acts as the nervous system of the entire organization, Organigram's team employs a data-driven decision-making process that ensures efficiency and top yields. Numerous design and automation improvements include an ergonomically friendly grow room design, automatic potting machines and automated packaging lines, and larger propagation rooms with advanced environmental systems.

Organigram's fully funded Phase 4 expansion is underway which, when complete by fall of 2019, will bring production capacity of high-quality premium cannabis to 113,000 kg/year (249,000 lbs). The Company has also invested in Hyasynth, a Montreal-based biotechnology company and leader in the field of cannabinoid science and biosynthesis. Hyasynth has developed a disruptive technology using patented enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation.

Organigram expects to double its workforce within the year to accommodate increasing growth as the facility expands to 480,000 square feet of production space at full buildout. In September 2017, Organigram signed the first ever recreational cannabis supply agreement in Canada with the Province of New Brunswick. Since then, Organigram has signed similar supply agreements with nine out of 10 provinces, has already exported product out of Canada, and is currently working with German medical cannabis provider, Alpha-cannabis, and Serbia-based Eviana Health Corp. (CSE: EHC), a hemp farm and processing facility.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado, with 16 retail locations, for development of commercial scale extraction and product processing, along with derivative product development (edibles, vaporizable products and beverage product mixes). Organigram's partnership with Canada's Smartest Kitchen, a leader in food product development, will expand and develop the Company's edibles R&D program and creation of premium chocolate products. Organigram has also signed a multi-year extraction contract with Valens GroWorks Corp. for Valens to produce extract concentrate for oils and derivative products.

Organigram is well-positioned in the cannabis space with several adult-use recreational product lines. These include:

  • Trailblazer offers a consistent value with a pre-roll, milled format
  • Trailer Park Buds provides niche equity for mainstream users that seek pre-rolls
  • Ankr Organics offers premium, organic pre-roll and oils
  • Edison Cannabis Co. delivers robust, high THC in a whole flower, pre-roll and oil produced from premium sorted flowers
  • Edison Cannabis Co. Reserve offers an ultra-premium, large whole flower that is craft cured and hand trimmed

Experienced Executive Team

  • CEO Gregory Engel has more than 30 years of experience in the pharmaceutical industry with over three years of experience as a CEO for a cannabis company.
  • Jeff Purcell, senior vice president of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods.
  • Tim Emberg, senior vice president of sales and commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and consumer packed good industry.
  • Guillermo Delmonte, president of international operations, brings experience in leading a global cannabis company and worked for 2.5 years as CEO of ICC Labs Inc. in Uruguay.
  • Larry Rogers, vice president of international operations, has held roles for Organigram since 2014 including being a member of the board of directors, chief operating officer and vice president/business development.
  • Paolo DeLuca, chief financial officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities.
  • Ray Gracewood, chief commercial officer, has 15 years of experience in the marketing space and is a previous senior director of sales and marketing for Moosehead Breweries Ltd.
  • Michael Tripp, chief legal officer, worked for private practices at respected business law firms in Moncton and Toronto where he acted on over $3 billion in transactions.

Organigram Holdings Inc. (NASDAQ: OGI), closed the day's trading session at $7.69, off by 2.04%, on 856,340 volume with 3,322 trades. The average volume for the last 3 months is 1,538,660 and the stock's 52-week low/high is $2.97/$8.44.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQB: PLPRF), a leading California edibles manufacturer, this morning announced the limited return of its popular Rainbow Sorbet gummies this June in support of the LGBTQ community during Pride month. To view the full press release, visit: http://nnw.fm/eeD7G.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $3.34, off by 5.41%, on 128,781 volume with 297 trades. The average volume for the last 3 months is 76,785 and the stock's 52-week low/high is $2.81/$6.01.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) was featured today in the 420 with CNW by CannabisNewsWire. A Spanish company, Hemp Trading, has developed a new cannabis strain that has no THC. This development became possible after the company partnered with UPV (Universitat Politecnica de Valencia) university in Spain. The new cannabis plant is expected to have numerous therapeutic benefits. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how the bullish momentum in cannabis stocks has continued in 2019.  Related stocks have already exploded on news of Canadian legalization, U.S. states approving its medicinal or recreational use, and corporate America interest.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.236118, off by 3.43%, on 366,835 volume with 554 trades. The average volume for the last 3 months is 581,572 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

Specialty chemical company Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF)this morning announced that its CEO, Robert Mintak, will present at this year’s LD Micro Invitational Conference, June 4-5, 2019, at the Luxe Sunset Hotel in Los Angeles, California. To view the full press release, visit http://nnw.fm/8zZlH.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $0.60, off by 0.55%, on 26,928 volume with 19 trades. The average volume for the last 3 months is 34,050 and the stock's 52-week low/high is $0.484/$1.387.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of premium cannabis products and services for the medical and adult-use markets and licensed producer of cannabis under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms") and ABcann Medicinals Inc. ("ABcann"), and its medical cannabis clinic network operated by Harvest Medicine Inc. ("Harvest Medicine"), today released its Q1 2019 financial and operating results.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.51292, off by 1.88%, on 71,583 volume with 54 trades. The average volume for the last 3 months is 255,725 and the stock's 52-week low/high is $0.413/$1.53.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article covering Vancouver-based Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), which develops and designs brands focused on plant-based health and wellness products, made several recent strategic moves demonstrating its commitment to becoming a global leader in the space. Also today, NetworkNewsWire released a report on the company detailing how WLDFF continues to expand the reach of its holistic plant product portfolio, inking an exclusive distribution agreement for the South African natural betterment market this month. Additionally, the company was recently featured in the article titled, ‘You Don’t Have to Wait for Marijuana Legalization to Get These CBD Products’ authored by Brain Halwell on edible Manhattan . To view the full article, visit: http://nnw.fm/g6g6L .

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.49, off by 0.17%, on 3,425 volume with 14 trades. The average volume for the last 3 months is 22,930 and the stock's 52-week low/high is $0.009/$1.129.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood, Inc. (OTCQB: NGTF), the innovative ice cream company solving America’s $50 billion-dollar nighttime snacking problem, conducted a quarterly investor conference call yesterday, May 28, 2019.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.49, off by 15.52%, on 979,130 volume with 329 trades. The average volume for the last 3 months is 296,098 and the stock's 52-week low/high is $0.16/$0.92.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.